Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic
review. Methods: Six databases were searched until March 2022 for studies assessing …

Since early 2020, the entire world has been facing a disastrous outbreak of the SARS-CoV-2
virus, with massive reporting of death and infections per day. Medical practitioners adopted …

In contrast to reports made early in the pandemic, we show XLA patients remain susceptible
to severe disease. Persistent infection was common and is likely to carry a significant …

Since its emergence, the COVID-19 pandemic has been ravaging the medical and
economic sectors even with the significant vaccination advances. In severe presentations …

Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several
drugs had been applied to treat patients with COVID-19, and repurposing colchicine had …

Background The aim of this randomized, controlled trial is to determine whether antisevere
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has become a global pandemic with a great impact on social …

Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …

Hospitalised patients with coronavirus disease 2019 (COVID-19) have a high mortality rate.
There are an increasing number of published randomised controlled trials for anti …

Abstract Background Anti‐SARS‐CoV‐2 S antibodies prevent viral replication. Critically ill
COVID‐19 patients show viral material in plasma, associated with a dysregulated host …